Advances in the Management of Central Nervous System Metastases from Breast Cancer

被引：4

作者：

Avila, Jorge ^{[1
,2
]}

Leone, Jose Pablo ^{[3
]}

机构：

[1] St Elizabeths Med Ctr, Dept Internal Med, 736 Cambridge St, Boston, MA 02135 USA

[2] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA

[3] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 20期

关键词：

breast cancer; brain metastases; metastatic breast cancer; central nervous system metastases; TRASTUZUMAB EMTANSINE T-DM1; BRAIN RADIATION-THERAPY; LAPATINIB PLUS CAPECITABINE; RANDOMIZED PHASE-III; DERUXTECAN T-DXD; STEREOTACTIC RADIOSURGERY; PROGNOSTIC-FACTORS; CNS METASTASES; DOUBLE-BLIND; INTRATHECAL TRASTUZUMAB;

D O I：

10.3390/ijms232012525

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Central nervous system (CNS) metastases are common in breast cancer (BC) patients and are particularly relevant as new treatments for BC are prolonging survival. Here, we review advances in the treatment of CNS metastases from BC, including radiotherapy, systemic therapies, and the evolving role of immunotherapy. The use of radiotherapy and chemotherapy is the cornerstone of treatment for CNS metastases. However, new targeted therapies have recently been developed, including anti-HER2 agents and antibody-drug conjugates that have presented promising results for the treatment of these patients.

引用

页数：22

共 134 条

[21] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer [J].

Burstein, Harold J. ;

Sun, Yan ;

Dirix, Luc Y. ;

Jiang, Zefei ;

Paridaens, Robert ;

Tan, Antoinette R. ;

Awada, Ahmad ;

Ranade, Anantbhushan ;

Jiao, Shunchang ;

Schwartz, Gary ;

Abbas, Richat ;

Powell, Christine ;

Turnbull, Kathleen ;

Vermette, Jennifer ;

Zacharchuk, Charles ;

Badwe, Rajendra .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1301-1307

[22] Characterization of Treatments and Disease Course for Women with Breast Cancer Brain Metastases: 5-Year Retrospective Single Institution Experience [J].

Chew, Sonya ;

Carroll, Hailey Kathryn ;

Darwish, Waseem ;

Boychak, Oleksandr ;

Higgins, Michaela ;

McCaffrey, John ;

Kelly, Catherine Margaret .

CANCER MANAGEMENT AND RESEARCH, 2021, 13 :8191-8198

[23] Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer [J].

Clayton, AJ ;

Danson, S ;

Jolly, S ;

Ryder, WDJ ;

Burt, PA ;

Stewart, AL ;

Wilkinson, PM ;

Welch, RS ;

Magee, B ;

Wilson, G ;

Howell, A ;

Wardley, AM .

BRITISH JOURNAL OF CANCER, 2004, 91 (04) :639-643

[24]

Committee for Medicinal Products for Human Use (CHMP), 2021, TUK INT NONPR NAM TU, P1

[25] Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer [J].

Cortes, J. ;

Rugo, H. S. ;

Cescon, D. W. ;

Im, S-A ;

Yusof, M. M. ;

Gallardo, C. ;

Lipatov, O. ;

Barrios, C. H. ;

Perez-Garcia, J. ;

Iwata, H. ;

Masuda, N. ;

Otero, M. Torregroza ;

Gokmen, E. ;

Loi, S. ;

Guo, Z. ;

Zhou, X. ;

Karantza, V ;

Pan, W. ;

Schmid, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03) :217-226

[26] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study [J].

Cortes, J. ;

Kim, S-B. ;

Chung, W-P. ;

Im, S-A. ;

Park, Y. H. ;

Hegg, R. ;

Kim, M. H. ;

Tseng, L-M. ;

Petry, V. ;

Chung, C-F. ;

Iwata, H. ;

Hamilton, E. ;

Curigliano, G. ;

Xu, B. ;

Lee, C. ;

Liu, Y. ;

Cathcart, J. ;

Bako, E. ;

Verma, S. ;

Hurvitz, S. A. .

ANNALS OF ONCOLOGY, 2021, 32 :S1287-S1288

[27] Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial [J].

Cortes, Javier ;

Rugo, Hope S. ;

Awada, Ahmad ;

Twelves, Chris ;

Perez, Edith A. ;

Im, Seock-Ah ;

Gomez-Pardo, Patricia ;

Schwartzberg, Lee S. ;

Dieras, Veronique ;

Yardley, Denise A. ;

Potter, David A. ;

Mailliez, Audrey ;

Moreno-Aspitia, Alvaro ;

Ahn, Jin-Seok ;

Zhao, Carol ;

Hoch, Ute ;

Tagliaferri, Mary ;

Hannah, Alison L. ;

O'Shaughnessy, Joyce .

BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (02) :329-341

[28]

Cottu PH, 2019, ANN ONCOL, V30, P118

[29] Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis [J].

Curigliano, G. ;

Mueller, V ;

Borges, V ;

Hamilton, E. ;

Hurvitz, S. ;

Loi, S. ;

Murthy, R. ;

Okines, A. ;

Paplomata, E. ;

Cameron, D. ;

Carey, L. A. ;

Gelmon, K. ;

Hortobagyi, G. N. ;

Krop, I ;

Loibl, S. ;

Pegram, M. ;

Slamon, D. ;

Ramos, J. ;

Feng, W. ;

Winer, E. .

ANNALS OF ONCOLOGY, 2022, 33 (03) :321-329

[30] Defining prognosis for women with breast cancer and CNS metastases by HER2 status [J].

Dawood, S. ;

Broglio, K. ;

Esteva, F. J. ;

Ibrahim, N. K. ;

Kau, S. -W. ;

Islam, R. ;

Aldape, K. D. ;

Yu, T. -K. ;

Hortobagyi, G. N. ;

Gonzalez-Angulo, A. M. .

ANNALS OF ONCOLOGY, 2008, 19 (07) :1242-1248

← 1 2 3 4 5 6 7 8 9 10 →